Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Psoriasis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Psoriasis
    Calcipotriene, Betamethasone Dipropionate Gel Approved in Europe for Scalp Psoriasis - (DGNews)
    European Commission Approves Once-Weekly Etanercept for Psoriasis - (DGNews)
    NICE Issues New Guidelines for Adalimumab in Adult Psoriasis - (DGNews)
    Malignancies in Etanercept-Treated Patients Uncommon: Presented at EULAR - (DGDispatch)
    Adalimumab Effective in Patients With Rheumatic Disease Unresponsive to Other Anti-TNF Therapies - (DGNews)

    News archive

     Recent webcasts/CME - Psoriasis
      Psoriasis and its Treatment
      Current Concepts in Psoriasis and Psoriatic Arthritis

      Webcasts/CME archive

       Recent cases - Psoriasis
        Concomitant Xeroderma Pigmentosum and Disseminated Small Plaque Psoriasis - The First Case of an Antinomic Association: A Case Report
        Extensive Psoriasis Induced by Pegylated Interferon: A Case Report
        Pulmonary Sarcoidosis Associated with Psoriasis Vulgaris: Coincidental Occurrence or Causal Association? Case Report
        Leukemia Cutis Resembling a Flare-Up of Psoriasis
        Pimecrolimus 1 Percent Cream in the Treatment of Psoriasis in a Child

        Cases archive
          




        my personal edition > psoriasis > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Adalimumab Shows Extraordinary Results in Moderate-to-Severe Plaque Psoriasis: Presented at AAD

        By Maggie Schwartz

        NEW YORK, NY -- August 4, 2004 -- Twenty four weeks of adalimumab therapy provided exceptional improvement in moderate-to-severe plaque psoriasis, according to study findings.

        Kenneth Gordon, MD, an associate professor of medicine at Loyola University, Chicago, Illinois, presented the results of a phase 2 trial of the tumor necrosis factor-blocking antibody at the American Academy of Dermatology Annual Summer Meeting held here July 28th to August 1st.

        Psoriasis is a chronic, noncontagious skin disease characterized by very dry, scaly, and cracked skin, skin pain, and patches of red, raised skin known as plaques. The disease is debilitating, has no cure, and affects more than 4.5 million Americans.

        The study included 148 individuals who had moderate-to-severe chronic plaque psoriasis of at least 1-year duration and with at least 5% of affected body surface area. They received subcutaneous injections of adalimumab, 40 mg, or placebo either every week or every other week for 24 weeks. The primary endpoint was the percentage of patients achieving at least a 75% reduction in disease activity after 24 weeks as measured by the Psoriasis Area and Severity Index Score (PASI 75) compared to baseline.

        Sixty-four percent of the patients who took adalimumab every other week achieved at least a 75% improvement in the extent and severity of their disease. Forty-two percent of those taking the drug every week achieved at least 90% improvement of their disease.

        The patients self-reported significant improvement in their quality of life. After 24 weeks, 40% said their quality of life was "not at all" affected by their psoriasis, as measured by the Dermatology Life Quality Index (DLQI), a measure of patient-reported outcomes in dermatology.

        Dr. Gordon reiterated that further study is required, that though encouraging, this was a phase 2 study only. "But anything to improve the lives of these subjects is a great help. This is a very disabling disease. Many sufferers don't even go outside. The quality-of-life implications are enormous, so it's important that we continue to seek out effect treatment options."


        [Presentation title: Results of the DLQI Dermatology-Specific Quality of Life Measure in Moderate to Severe Plaque Psoriasis Patients Receiving 24 Weeks of Adalimumab Therapy]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send